### Fiscal Year 2024 Department of Defense Peer Reviewed Orthopaedic Research Program (PRORP)

**Reference Table of Award Mechanisms and Submission Requirements**

<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Applied Research Award (ARA)     | Independent investigators at all academic levels (or equivalent)             | • Supports applied research applications focused on advancing optimal treatment and restoration of function for individuals with orthopaedic injuries sustained during combat and service-related activities.  
• Proposed research should be supported by preliminary and/or published data and have the potential to advance toward clinical translation.  
• Funding must support preclinical applied research.  
• Clinical research, including clinical trials, are not allowed under this award mechanism.  
• Applications must address one of the following FY24 PRORP ARA Focus Areas:  
  o Limb Stabilization and Protection  
  o Retention Strategies (Battlefield Care only)  
  o Osseointegration  
  o Composite Tissue Regeneration  
• Pre-application submission is required; application submission is by invitation only. | • The maximum allowable funding for the entire period of performance is $750,000 in total costs.  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.  
• The maximum period of performance is 3 years. | Pre-Application (Preproposal):  
June 18, 2024  
5:00 p.m. Eastern time (ET)  
Application:  
September 17, 2024  
11:59 p.m. ET |

**Go to:**
- Program Announcement
- General Application Instructions

**Grants.gov Funding Opportunity Number:**
HT942524PRORPARA
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Clinical Trial Award (CTA) | Independent investigators at all academic levels (or equivalent) | • Supports the rapid implementation of clinical trials with the potential to have a significant impact on treatment or management of military combat or service-related orthopaedic injuries that significantly impact unit readiness and return-to-duty/work rates.  
• **Funding must support a clinical trial and may not be used for animal or preclinical research studies.**  
• Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration or other relevant national regulatory agency **within 6 months of the award date.**  
• Applications must address one of the following FY24 PRORP CTA Focus Areas:  
  o **Limb Stabilization and Protection**  
  o **Retention Strategies**  
    ▪ Battlefield Care  
    ▪ Return to Duty  
  o **Translation of Early Findings**  
    ▪ Soft Tissue Trauma  
    ▪ Fracture-Related Infection  
  o **Prostheses and Orthoses**  
• All applications, regardless of the selected Focus Area, are eligible for **Research Level 1.**  
• Applications submitted to address the *Translation of Early Findings – Soft Tissue Trauma Focus Area* and include the Collaborative Care Option are eligible for **Research Level 2.**  
• **Pre-application submission is required; application submission is by invitation only.** | **Research Level 1:**  
• The maximum allowable funding for the entire period of performance is **$2.5 million (M)** in total costs.  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.  
• The maximum period of performance is **4 years.**  
**Research Level 2:**  
• The maximum allowable funding for the entire period of performance is **$3.25M** in total costs.  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.  
• The maximum period of performance is **4 years.** | **Pre-Application (Preproposal):**  
June 18, 2024  
5:00 p.m. ET  
**Application:**  
September 17, 2024  
11:59 p.m. ET |

Grants.gov Funding Opportunity Number:  
HT942524PRORPCTA
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Clinical Translational Research Award (CTRA) | Independent investigators at all academic levels (or equivalent) | • Supports high-impact and/or emerging clinical research that may not be ready for a full-scale randomized controlled clinical trial.  
• Funding must support clinical research studies involving humans.  
• Animal research is not allowed under this award mechanism.  
• Preliminary data relevant to the proposed research project are required.  
• Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration or other relevant national regulatory agency within 12 months of the award date.  
• Applications must address one of the following FY24 PRORP CTRA Focus Areas:
  o Retention Strategies
    ▪ Battlefield Care
    ▪ Return to Duty
  o Volumetric Muscle Loss
  o Composite Tissue Regeneration
  o Osseointegration  
• Pre-application submission is required; application submission is by invitation only. | • The maximum allowable funding for the entire period of performance is $1.5M in total costs.  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.  
• The maximum period of performance is 4 years. | **Pre-Application (Preproposal):**  
June 18, 2024  
5:00 p.m. ET  
**Application:**  
September 17, 2024  
11:59 p.m. ET |
<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Women’s Health Research Award (WHRA) | Independent investigators at all academic levels (or equivalent) | • Submission of a letter of intent is required; an invitation to submit a full application is not required.  
• Supports research focused on orthopaedic issues faced by women serving in military settings, such as infantry and other physically demanding roles, who have sustained orthopaedic injuries.  
• Applications are encouraged from a spectrum of research areas, including but not limited to translational and clinical research.  
• Qualitative research, population science, and health care services research specifically designed to understand the impact of orthopaedic injuries on female Service Members is also welcome.  
• **Clinical trials are not allowed under this award mechanism.**  
• Inclusion of female military and/or Veteran populations is highly encouraged for applications proposing clinical research. Use of military populations, datasets, or samples are not required; however, the application should demonstrate how the proposed research relates to issues faces by women serving in military settings.  
• No FY24 PRORP Focus Areas are required to be addressed for this award mechanism. Applications must directly address women’s health as it relates to **orthopaedic injury care/treatment or outcomes.** | • The maximum allowable funding for the entire period of performance is **$1.5M** in total costs.  
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.  
• The maximum period of performance is 3 years. | Pre-Application (LOI):  
August 21, 2024  
5:00 p.m. ET  

Application:  
September 17, 2024  
11:59 p.m. ET |